Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GRCE)

Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update

GlobeNewswire 8 days ago

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

GlobeNewswire October 30, 2024

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

GlobeNewswire October 25, 2024

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

GlobeNewswire September 25, 2024

Acasti to Present at the Life Sciences Investor Forum

GlobeNewswire September 12, 2024

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

GlobeNewswire August 9, 2024

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

GlobeNewswire June 27, 2024

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

GlobeNewswire June 21, 2024
View More News ››

Opinion & Analysis (NDAQ:GRCE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GRCE)

Acasti Pharma (NASDAQ:ACST): A Promising Specialty Pharmaceu

http://beyondspx.com/2024/07/31/acasti-pharma-nasdaqacst-a-promising-specialty-pharmaceutical-company-focused-on-rare-and-orphan-diseases...
MikeTester - August 2, 2024

the perfect situation

With a market cap  trading  under the cash in the cie and 3 products in clinic phase announcing news in the coming weeks you...
bingostar - December 22, 2022

RE:GTX-104 positive results

No One is paying attention to them, look at the decline in share price, its hard to believe they are still around, glad I dumped when...
Canadian_101 - November 21, 2022

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting...
bingostar - May 18, 2022

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today...
Betteryear2 - April 25, 2022

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never...
alanmar1 - April 3, 2022
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp., formerly Medgold Resources Corp., is a Canada-based mineral exploration and development company ...
View More »